|
Fig. 8 Parallels and contrast between HRAS-OE and regenerating ventricle in zebrafish. (A) Advantages of the newly established cmlc2:Gal4-ERT2 transgenic model. (B) Phenotypic and molecular characterization of the overgrowth caused by expression of the oncogenic HRASG12V for 16 days in the adult heart. (C) Molecular mechanisms underlying rescue of cardiac overgrowth by rapamycin treatment. (D) Selected genes, pathways and biological processes that are commonly and distinctively deregulated in HRAS-OE and regenerating hearts. (E) The beneficial effect of short-term expression of oncogenic HRAS on subsequent cardiac regeneration after cryoinjury.